AusperBio

Antios Therapeutics

This clinical-stage biopharmaceutical company develops antiviral therapies to treat and cure patients with chronic hepatitis B virus infections.

nChroma Bio

The company develops liver-targeted epigenetic editing therapies and non-viral delivery systems to treat patients with chronic hepatitis B and hepatitis D.

Bluejay Therapeutics

The company develops monoclonal antibody therapies and small molecule drugs to treat patients with chronic hepatitis B, hepatitis D and other liver diseases.

Atea Pharmaceuticals

This biopharmaceutical company develops oral antiviral therapies to treat patients with serious viral infections, including hepatitis C and hepatitis E.

Creyon Bio

This company develops AI-designed oligonucleotide-based medicines and RNA-targeted therapies for pharmaceutical partners and patients with neuromuscular and immunological diseases.

Agenovir

This company develops nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes for healthcare providers treating patients with persistent viral infections.

Spot Biosystems

This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.

IntrepidiaBio

This biopharmaceutical company develops therapeutic products to address unmet medical needs for patients.